{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:25:50Z","timestamp":1786123550290,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Emotional well-being and brain aging are increasingly understood as overlapping outcomes shaped by inflammatory, neuroimmune, vascular, and metabolic processes. This structured critical narrative review evaluates eicosapentaenoic acid (EPA) as a mechanistically distinct omega-3 fatty acid while explicitly separating EPA-specific evidence from mixed omega-3, fish-intake, and biomarker-status evidence. Particular attention is given to EPA-derived specialized pro-resolving mediators, especially E-series resolvins, and to the hypothesis that EPA may influence brain-relevant outcomes through peripheral inflammatory resolution, endothelial signaling, blood-brain barrier function, neurovascular pathways, and the peripheral immune-brain axis. The current evidence is heterogeneous and differs substantially in directness. EPA-predominant evidence is most developed for depressive symptoms, whereas brain-aging and imaging evidence is often based on fish intake, total omega-3 exposure, or red blood cell EPA+DHA status rather than isolated EPA intervention. This review therefore interprets such evidence as hypothesis-generating rather than as proof of EPA-specific effects. Differences in EPA dose, EPA:DHA ratio, formulation, placebo choice, duration, background diet, baseline omega-3 status, baseline inflammation, clinical phenotype, concomitant treatment, and endpoint selection are examined as potential sources of heterogeneity. The review proposes a testable peripheral-to-central resolution-biology framework for future biomarker-informed research, not a validated clinical decision pathway or universal intervention. EPA is best evaluated as a candidate research exposure whose relevance depends on biological context, verified exposure, inflammatory phenotype, and mechanism-aligned outcomes.<\/jats:p>","DOI":"10.3389\/fnut.2026.1878417","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:12:14Z","timestamp":1786115534000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Eicosapentaenoic acid in emotional well-being and brain aging: evidence boundaries, clinical heterogeneity, and a peripheral-to-central resolution-biology framework"],"prefix":"10.3389","volume":"13","author":[{"given":"Qihui","family":"Peng","sequence":"first","affiliation":[{"name":"Foresight Life Science Pte. Ltd.","place":["Singapore, Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.4088\/JCP.10m06634","article-title":"Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression.","volume":"72","author":"Sublette","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41398-019-0515-5","article-title":"Efficacy of omega-3 PUFAs in depression: a meta-analysis.","volume":"9","author":"Liao","year":"2019","journal-title":"Transl Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000502652","article-title":"International society for nutritional psychiatry research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder.","volume":"88","author":"Guu","year":"2019","journal-title":"Psychother Psychosom"},{"key":"B4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1017\/S000711452300226X","article-title":"Clinical impacts of n-3 fatty acids supplementation on depression symptoms: an umbrella review of meta-analyses.","volume":"131","author":"Lu","year":"2024","journal-title":"Br J Nutr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1017\/S0007114523002052","article-title":"Efficacy and safety of n-3 fatty acids supplementation on depression: a systematic review and dose-response meta-analysis of randomised controlled trials.","volume":"131","author":"Norouziasl","year":"2024","journal-title":"Br J Nutr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.3390\/nu16213688","article-title":"The efficacy of omega-3 fatty acids as the monotherapy for depression: a randomized, double-blind, placebo-controlled pilot study.","volume":"16","author":"Wu","year":"2024","journal-title":"Nutrients"},{"key":"B7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jad.2025.03.006","article-title":"Exploration of the optimized portrait of omega-3 polyunsaturated fatty acids in treating depression: A meta-analysis of randomized-controlled trials.","volume":"379","author":"Kong","year":"2025","journal-title":"J Affect Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1001\/jama.2021.21187","article-title":"Effect of long-term supplementation with marine omega-3 fatty acids vs. placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial.","volume":"326","author":"Okereke","year":"2021","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD004692","DOI":"10.1002\/14651858.CD004692.pub5","article-title":"Omega-3 fatty acids for depression in adults.","volume":"11","author":"Appleton","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/nu14091827","article-title":"The effects of omega-3 supplementation on depression in adults with cardiometabolic disease: a systematic review of randomised control trials.","volume":"14","author":"Arsenyadis","year":"2022","journal-title":"Nutrients"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20163","DOI":"10.1002\/cam4.6598","article-title":"Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: secondary analysis of a double-blind placebo-controlled randomized trial.","volume":"12","author":"Savard","year":"2023","journal-title":"Cancer Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41386-022-01527-7","article-title":"Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators.","volume":"48","author":"Lamon-Fava","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"102219","DOI":"10.1016\/j.plefa.2020.102219","article-title":"Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation.","volume":"164","author":"Lamon-Fava","year":"2021","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3389\/fphar.2019.01022","article-title":"N-3 polyunsaturated fatty acids and the resolution of neuroinflammation.","volume":"10","author":"Joffre","year":"2019","journal-title":"Front Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"673549","DOI":"10.3389\/fncel.2021.673549","article-title":"Specialized pro-resolving lipid mediators and glial cells: emerging candidates for brain homeostasis and repair.","volume":"15","author":"Tiberi","year":"2021","journal-title":"Front Cell Neurosci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.3390\/molecules27154836","article-title":"Specialized pro-resolving mediators in neuroinflammation: overview of studies and perspectives of clinical applications.","volume":"27","author":"Valente","year":"2022","journal-title":"Molecules"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.1038\/s41380-021-01160-8","article-title":"Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis.","volume":"26","author":"Borsini","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1021\/cr100396c","article-title":"Resolvins and protectins in inflammation resolution.","volume":"111","author":"Serhan","year":"2011","journal-title":"Chem Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1535094","DOI":"10.3389\/fnagi.2025.1535094","article-title":"Strategic delivery of omega-3 fatty acids for modulating inflammatory neurodegenerative diseases.","volume":"17","author":"Chen","year":"2025","journal-title":"Front Aging Neurosci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41398-024-02932-w","article-title":"Omega-3 fatty acids and major depression: a Mendelian randomization study.","volume":"14","author":"Carnegie","year":"2024","journal-title":"Transl Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"645646","DOI":"10.3389\/fphys.2021.645646","article-title":"Lipid transport and metabolism at the blood-brain interface: implications in health and disease.","volume":"12","author":"Pifferi","year":"2021","journal-title":"Front Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3390\/cells13211791","article-title":"Omega-3 fatty acids and neuroinflammation in depression: targeting damage-associated molecular patterns and neural biomarkers.","volume":"13","author":"Malau","year":"2024","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","first-page":"30610","DOI":"10.1038\/s41598-025-16129-8","article-title":"A systematic review and dose response meta analysis of Omega 3 supplementation on cognitive function.","volume":"15","author":"Shahinfar","year":"2025","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/nu17183002","article-title":"Omega-3 polyunsaturated fatty acids and cognitive decline in adults with non-dementia or mild cognitive impairment: an overview of systematic reviews.","volume":"17","author":"Barros","year":"2025","journal-title":"Nutrients"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e12288","DOI":"10.1002\/trc2.12288","article-title":"Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial.","volume":"8","author":"Kang","year":"2022","journal-title":"Alzheimers Dement (N Y)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/ajcn\/nqac236","article-title":"Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the alzheimer\u2019s disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses.","volume":"116","author":"Rouch","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1212\/WNL.0000000000000080","article-title":"Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study.","volume":"82","author":"Pottala","year":"2014","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2572","DOI":"10.1212\/WNL.0000000000201296","article-title":"Association of red blood cell omega-3 fatty acids with MRI markers and cognitive function in midlife: the Framingham Heart Study.","volume":"99","author":"Satizabal","year":"2022","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.3233\/JAD-220863","article-title":"N-3 Polyunsaturated fatty acids in elderly with mild cognitive impairment: a systemic review and meta-analysis.","volume":"99","author":"Yang","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21m14074","DOI":"10.4088\/JCP.21m14074","article-title":"Omega-3 fatty acids for major depressive disorder with high inflammation: a randomized dose-finding clinical trial.","volume":"83","author":"Mischoulon","year":"2022","journal-title":"J Clin Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ypmed.2004.02.030","article-title":"The Omega-3 Index: a new risk factor for death from coronary heart disease?","volume":"39","author":"Harris","year":"2004","journal-title":"Prev Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.cir.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"B33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs. corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the strength randomized clinical trial.","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1878417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:12:15Z","timestamp":1786115535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1878417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":34,"alternative-id":["10.3389\/fnut.2026.1878417"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1878417","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"article-number":"1878417"}}